Compare GRFS & G Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRFS | G |
|---|---|---|
| Founded | 1940 | 1997 |
| Country | Spain | Bermuda |
| Employees | 25247 | 140000 |
| Industry | Biotechnology: Pharmaceutical Preparations | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 5.8B |
| IPO Year | N/A | 2007 |
| Metric | GRFS | G |
|---|---|---|
| Price | $8.48 | $36.54 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 6 |
| Target Price | $10.15 | ★ $49.50 |
| AVG Volume (30 Days) | 649.3K | ★ 2.2M |
| Earning Date | 07-28-2022 | 05-07-2026 |
| Dividend Yield | 1.63% | ★ 2.03% |
| EPS Growth | N/A | ★ 9.82 |
| EPS | N/A | ★ 3.13 |
| Revenue | N/A | ★ $2,279,438,000.00 |
| Revenue This Year | $4.69 | $9.20 |
| Revenue Next Year | $6.49 | $7.27 |
| P/E Ratio | $18.67 | ★ $11.80 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.90 | $33.92 |
| 52 Week High | $11.14 | $50.24 |
| Indicator | GRFS | G |
|---|---|---|
| Relative Strength Index (RSI) | 53.66 | 45.30 |
| Support Level | $8.27 | $34.36 |
| Resistance Level | $9.08 | $38.42 |
| Average True Range (ATR) | 0.21 | 1.08 |
| MACD | 0.09 | 0.12 |
| Stochastic Oscillator | 67.73 | 58.78 |
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.
Genpact Ltd is an agentic, technology-solutions company offering digital transformation, data-driven operations, and technology-enabled services across multiple industries. Its core business services include decision support services; technology services like application lifecycle management, platform customization, and support, etc; and digital operations optimizing business processes. Genpact also offers data engineering, data management, and domain-based AI and generative AI solutions; develops new technology solutions for clients; and offers agentic solutions and technology consulting services. Its reportable segments are: High Tech and Manufacturing, which generate maximum revenue, Financial Services, and Consumer and Healthcare. Geographically, it derives maximum revenue from India.